Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and Qiagen Manchester Ltd., a wholly owned subsidiary of Qiagen, said today that they have inked a master assay development, commercialization, and manufacturing agreement.

The agreement creates a framework for the companies to combine their technological and commercial strengths to offer pharmaceutical companies a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests, with a focus on oncology.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.